Imatinib, an inhibitor of PDGFR alpha and beta kinases, as well as other selected tyrosine kinases (Abl and KIT), is indicated for treatment of CML, myeloid cancers with PDGFR translocations and gastrointestinal stromal tumour. Here, PDGFRB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.